Collegium Pharmaceutical, Inc (COLL) · Aug 6, 2026 · Company update

ADHD momentum beat earnings expectations, but guidance took a meaningful hit

ADHD momentum beat earnings expectations, but guidance took a meaningful hit

The quarter beat on adjusted earnings but slightly missed on revenue. Product revenue was $199.9 million versus a published consensus of roughly $203 million, while adjusted EPS was $1.92 versus approximately $1.72 expected. Adjusted EBITDA reached $113.8 million, up 8% year over year, but the revenue shortfall means the headline operating performance was not a clean beat. (Income Statement; Adjusted EBITDA reconciliation)

MetricQ2 2026Q2 2025 / expectationRead
Product revenue$199.9M$188.0M / ~$203M consensus+6% year over year; slight miss to consensus (Income Statement)
Adjusted EBITDA$113.8M$105.1M+8% year over year (Adjusted EBITDA reconciliation)
Adjusted net income$75.4M$64.3M+17% year over year (Adjusted net income reconciliation)
Adjusted EPS$1.92$1.68 / ~$1.72 consensusBeat (Adjusted net income reconciliation)
GAAP net income$(15.1)M$12.0MReversed to a loss (Income Statement)

The forward reset is the more important message than the quarterly beat. Full-year product-revenue guidance fell from $865–895 million to $825–855 million, cutting the midpoint by $40 million, while adjusted EBITDA guidance fell from $475–500 million to $445–470 million, a $30 million midpoint reduction. Management attributed both cuts primarily to lower net pricing on authorized-generic Nucynta revenue; JORNAY PM guidance was unchanged, and AZSTARYS guidance increased to $65–75 million from $60–70 million. (2026 Financial Guidance table)

The growth engine is working, but the legacy pain business is deteriorating faster than expected. The ADHD portfolio generated $140.9 million in Q2 revenue, including $12.9 million from AZSTARYS during its partial quarter, while JORNAY PM prescriptions rose 13.1% and its branded long-acting methylphenidate share increased to 29%. Against that, Nucynta franchise revenue fell 24% year over year to $35.2 million, including $5.1 million from authorized generics. The filing therefore supports stronger ADHD execution, but not enough to offset pricing pressure in pain. (Earnings presentation, Recent Business Highlights; Earnings presentation, Product Utilization; Press Release, Commercial Update)

AZSTARYS integration is an operational positive, not yet a proven financial offset. The acquisition closed in May, the expanded sales force was trained ahead of back-to-school demand, and revenue guidance was raised. But the company still expects only a partial-year contribution, while acquisition-related expenses reached $24.1 million in the quarter and intangible amortization was $63.0 million. The claimed long-term benefits remain forward-looking; the immediate filing shows added complexity and spending alongside the new growth opportunity. (Commercial Update; AZSTARYS Portfolio slide; Adjusted EBITDA reconciliation)

The net read is negative because the guidance cut outweighs the EPS beat. Cash and marketable securities fell from $386.7 million at December 31, 2025 to $129.5 million at June 30, 2026, while term notes payable increased to $852.8 million from $571.1 million after the acquisition. The company reports net debt at 2.1 times adjusted EBITDA, leaving less room for execution mistakes. In short: ADHD momentum and adjusted profitability were better than feared, but the market now has to absorb lower full-year revenue and EBITDA expectations, plus greater balance-sheet leverage. (Balance Sheet; Earnings presentation, Disciplined Capital Deployment)

Original filing on SEC EDGAR

More Collegium Pharmaceutical, Inc news

ADHD momentum beat earnings expectations, but guidance took a meaningful hit | COLL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.